A US drug company that faced criticism after raising the price of a drug that is used by Aids patients by over 5,000 per cent has now agreed to lower its price.
Martin Shkreli, the head of Turing Pharmaceuticals, said that he will drop the prices of the drug after the outcry, but has not revealed the amount, reports the BBC.
Turing Pharmaceuticals acquired the rights to Daraprim in August after which it increased the price of the drug from 13.50 dollars to 750 dollars.
Talking about the incident, US presidential candidate Hillary Clinton said that she will make pharmaceutical companies put more money into research if she is elected.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app